Suggested remit - To appraise the clinical and cost effectiveness of ticagrelor within its marketing authorisation for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease
Status Proposed
Process STA 2018
ID number 1514

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
14 January 2019 (10:00) Scoping workshop (Manchester)
16 November 2018 - 14 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance